Genflow Biosciences to hold AGM on 29 June 2026

Genflow Biosciences Plc (LON:GENF)(OTCQB:GENFF), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, has announced that it will hold its Annual General Meeting (AGM) at 11am on Monday 29 June 2026 at One Heddon Street, London, W1B 4BD.

The Notice of the AGM and Form of Proxy will shortly be available on the Company’s website, www.genflowbio.com, and have, where applicable, been posted to shareholders. Further details of the arrangements for this year’s AGM are set out in the Notice.

As announced on 30 April 2026, the Company’s Annual Report and Accounts for the year ended 31 December 2025 are also available on the website and have, where applicable, also been posted to shareholders.

Share on:

Written by: Amilia Stone

Find more news, interviews, share price & company profile here for:
Genflow Biosciences Plc

Latest Company News

Genflow reports SIRT6 gene therapy results in aged dogs

October 5, 2026

Genflow reports reduced epigenetic age in dogs treated with its SIRT6c gene therapy, with pDNA selected as the lead delivery method for its veterinary programme.

Genflow completes SLAB trial as human and animal health programmes advance

September 29, 2026

Genflow Biosciences completed its SLAB canine healthspan and sarcopenia trial in H1 2026, with the company reporting safety and tolerability data for GF-1004. The group also advanced its glaucoma, MASH, Mitosir and Exofastrack programmes while ending the period with £632,553 in cash.

Age-related disease keeps biotechnology research in focus

September 22, 2026

Age-related conditions such as glaucoma and sarcopenia continue to support interest in biotechnology research focused on the biology of ageing.

Genflow advances SIRT6 gene therapy

September 14, 2026

Genflow Biosciences has met the primary endpoint in its aged-dog SIRT6 gene therapy trial, adding biological evidence for its platform as the company progresses animal health partnership discussions.